Scarica l'app Stockscreener
0.317
5.07%
0.0153
Rallybio Corp Borsa (RLYB) Ultime notizie
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - BioSpace
Rallybio Makes Nasdaq Debut - RTTNews
Citizens JMP maintains Rallybio stock at Market Perform By Investing.com - Investing.com Nigeria
Citizens JMP maintains Rallybio stock at Market Perform - Investing.com
Rallybio (NASDAQ:RLYB) Cut to Hold at Evercore ISI - Defense World
Rallybio drops drug for rare maternal disorder following Phase II fail - MSN
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Evercore ISI Downgrades Rallybio to In Line From Outperform - marketscreener.com
Analysts Set Rallybio Co. (NASDAQ:RLYB) Price Target at $9.75 - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns - Investing.com Australia
Rallybio’s (RLYB) Neutral Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Estimates Rallybio’s Q2 Earnings (NASDAQ:RLYB) - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns By Investing.com - Investing.com India
Rallybio (NASDAQ:RLYB) Cut to Hold at Citizens Jmp - Defense World
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Rallybio to Neutral From Buy - MarketScreener
Rallybio sinks as it drops RLYB212 for prevention of FNAIT - The Pharma Letter
Rallybio ends RLYB212 program after trial setback - Investing.com Australia
Citizens JMP cuts Rallybio stock rating following program halt By Investing.com - Investing.com Canada
Rallybio stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Citizens JMP cuts Rallybio stock rating following program halt - Investing.com Australia
Rallybio stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Rallybio Corporation to Discontinue Development of RLYB212 for Prevention of FNAIT - MarketScreener
Citizens JMP downgrades Rallybio on RLYB212 discontinuation - TipRanks
Rallybio pulls plug on rare pregnancy blood disorder treatment - FirstWord Pharma
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints - Benzinga
Rallybio discontinues lead drug for rare maternal disorder - BioPharma Dive
Rallybio Pivots as Antibody for Rare Bleeding Disorder Flunks Dosing Trial - BioSpace
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
New Haven-based Rallybio discontinues development of rare disease therapy - Hartford Business Journal
Rallybio shares tumble 36% after RLYB212 program halt By Investing.com - Investing.com South Africa
Rallybio shares tumble 36% after RLYB212 program halt - Investing.com India
Rallybio Corp Discontinues Rlyb212 Program For Prevention Of Fnait - marketscreener.com
Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint - Fierce Biotech
Rallybio ends RLYB212 program after trial setback By Investing.com - Investing.com India
Rallybio discontinues RLYB212 program - TipRanks
Major Pipeline Shift: Rallybio Abandons FNAIT Drug to Target Lucrative $6B Disease Market - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday SessionAgilon Health (NYSE:AGL), Alumis (NASDAQ:ALMS) - Benzinga
Rallybio stock plunges to 52-week low, hitting $0.6 - Investing.com Australia
Rallybio stock plunges to 52-week low, hitting $0.6 By Investing.com - Investing.com India
Rallybio stock plunges to 52-week low at $0.62 amid market challenges - Investing.com Canada
Rallybio stock plunges to 52-week low at $0.62 amid market challenges By Investing.com - Investing.com South Africa
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):